Connection
Jennifer Trujillo to Glucagon-Like Peptide-1 Receptor
This is a "connection" page, showing publications Jennifer Trujillo has written about Glucagon-Like Peptide-1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.820 |
|
|
|
-
Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
Score: 0.790
-
Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep; 45 Suppl 1:43-60.
Score: 0.684
-
Trujillo JM, Goldman J. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy. 2017 Aug; 37(8):927-943.
Score: 0.551
-
Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020 11 17; 173(10):813-821.
Score: 0.171
-
Johnson EL, Frias JP, Trujillo JM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med. 2018 May; 130(4):365-374.
Score: 0.144
-
Goldman J, Trujillo JM. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Ann Pharmacother. 2017 Nov; 51(11):990-999.
Score: 0.137
-
Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015 Mar; 49(3):351-9.
Score: 0.116
-
Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
Score: 0.114
-
Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov; 48(11):1494-501.
Score: 0.112